Compare CDLX & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDLX | MIRA |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 43.7M |
| IPO Year | 2018 | 2023 |
| Metric | CDLX | MIRA |
|---|---|---|
| Price | $4.69 | $0.97 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.25 | N/A |
| AVG Volume (30 Days) | ★ 648.5K | 122.1K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $233,273,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $0.90 |
| 52 Week High | $6.40 | $2.45 |
| Indicator | CDLX | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 85.73 | 46.04 |
| Support Level | $0.86 | $0.91 |
| Resistance Level | N/A | $1.22 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | 0.43 | -0.00 |
| Stochastic Oscillator | 70.77 | 15.96 |
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.